Anti-BCL10 Antibody (BL10/411)

Anti-BCL10 Antibody (BL10/411)is available at Gentaur for Next week Delivery.

Description: BCL10, with an N-terminal caspase recruitment domain (CARD), is found in a number of apoptotic regulatory molecules. It was identified through its direct involvement in t(1;14) of mucosa-associated lymphoid tissue (MALT) lymphoma. Expression of BCL10 was shown to induce NFĪŗB activation in a NIK-dependent pathway. This MAb labels subpopulations of normal B and T cells and is a useful tool for the sub-classification of lymphomas. In MALT lymphomas with the t(1;14) translocation, while 55% of MALT lymphomas lacking this translocation exhibited the same labeling pattern, although at a much lower level.

Immunogen Sequence:Human BCL10 recombinant protein (epitope aa122-168)

Target Alternative Name:B-cell CLL/lymphoma 10, B-cell leukemia/lymphoma 10, CARD-containing molecule enhancing NF-kappa-B, CARD-like apoptotic protein, caspase-recruiting domain-containing protein, CED-3/ICH-1 prodomain homologous E10-like regulator, Cellular homolog of vCARMEN, Cellular-E10 (cE10), CIPER, hCLAP, mE10, R-RCD1

Species Reactivities:Human

Tag Line:Monoclonal antibody to detect BCL10 in human samples

Formulation:In 10 mM PBS with 0.05% BSA & 0.05% azide

Purification: Protein A/G purification

Application:FC, IF, IHC, WB

Positive Control:WB: HepG2 cells, IHC: human Tonsil

Application And Usages:FC: 0.5-1 ug/1X106 cells, IF: 1-2 ug/ml, WB: 0.5-1ug/ml, IHC: 0.5-1 ug/ml

Handling:The antibody solution should be gently mixed before use.